| abstract |
This paper describes the Bruton's tyrosine kinase (Btk) inhibitor 1‑((R)‑3‑(4‑amino‑3‑(4‑phenoxyphenyl)‑1H‑pyrazolo[3, A medicinal formulation of 4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using Btk inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer (including lymphoma), and inflammatory diseases or conditions. |